Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03343301 · ClinicalTrials.gov registry record · Phase 1
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer
A Phase 1 study, sponsored by Five Prime Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03343301 is a Phase 1 study that has completed, run by Five Prime Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT03343301, a Phase 1 study, has completed, sponsored by Five Prime Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The primary objective of the phase 1 portion of this study is to determine the recommended dose of bemarituzumab in combination with 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) to use in the phase 2 portion of the trial.
Interventions
- DRUG Modified FOLFOX6
- BIOLOGICAL Bemarituzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-11-30 |
| Est. Completion | 2019-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03343301
The ClinicalTrials.gov registry entry for NCT03343301 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Five Prime Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Modified FOLFOX6 is the first listed.
NCT03343301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03343301 about?
NCT03343301 is a clinical study titled "A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer". The primary objective of the phase 1 portion of this study is to determine the recommended dose of bemarituzumab in combination with 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) to use in the phase 2 portion of the trial.
What is the current status of trial NCT03343301?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2017-11-30. Estimated completion is 2019-01-31.
What interventions are being tested in trial NCT03343301?
The interventions under investigation include: Modified FOLFOX6 (DRUG), Bemarituzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03343301?
This trial is sponsored by Five Prime Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.